A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD.

@article{Liesker2002ASR,
  title={A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD.},
  author={Jeroen J. W. Liesker and Peter Jan Wijkstra and Nick H. T. ten Hacken and Gerard H. Ko{\"e}ter and Dirkje S Postma and Huib A. M. Kerstjens},
  journal={Chest},
  year={2002},
  volume={121 2},
  pages={
          597-608
        }
}
One of the major goals of bronchodilator therapy in patients with COPD is to decrease airflow limitation in the airways and, as a consequence, improve dyspnea and exercise tolerance. The focus of this systematic review is to assess the effects of treatment with beta-agonists, anticholinergics, and theophyllines on dyspnea, and steady-state and incremental exercise capacity. Thirty-three, double-blind, randomized, placebo-controlled studies written in English were selected. This review shows… Expand
Impact of bronchodilator therapy on exercise tolerance in COPD
  • B. Aguilaniu
  • Medicine
  • International journal of chronic obstructive pulmonary disease
  • 2010
TLDR
The link between expiratory flow limitation and dyspnea is examined to explain the rationale for the use of bronchodilators and the characteristics of different types of exercise tests are reviewed, with specific focus on which tests are likely to show a response to bronchidilators. Expand
Effect of theophylline on exercise capacity in COPD patients treated with combination long-acting bronchodilator therapy: a pilot study
TLDR
This study demonstrated a trend, but not a statistically significant improvement in exercise duration and a reduction in peak ventilation with theophylline, which is a widely available medication which may further improve lung function and exercise performance. Expand
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD
TLDR
Results show that the use of tiotropium was associated with sustained reductions of lung hyperinflation at rest and during exercise and contributed to improvements in both exertional dyspnoea and exercise endurance. Expand
A comparison of the effects of salbutamol and ipratropium bromide on exercise endurance in patients with COPD.
TLDR
Therapy with both salbutamol and ipratropium bromide improved exercise capacity, as evaluated by the endurance time, and reduced dyspnea similarly in patients with COPD, supporting the conclusion that both types of inhaled bronchodilators can be used as first-line drugs for the treatment of stable patients with CAS. Expand
Effects of short-acting bronchodilators added to maintenance tiotropium therapy.
TLDR
Both short-acting bronchodilator classes were effective when added to maintenance treatment with tiotropium, and the addition of the beta2-adrenergic fenoterol provided greater additional bron chodilatation than the short- acting anticholinergic ipratropium. Expand
Acute administration of bronchodilators on exercise tolerance in treated COPD patients.
TLDR
Although a single-dose salbutamol/ipratropium + flunisolide (BD+ICS) did not improve ET in COPD patients under regular treatment, a subgroup of more severe patients may have some benefit from that. Expand
Single Dose of Tiotropium Improves the 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease
TLDR
It is concluded that exercise capacity might be improved by using a single-dose tiotropium inhalation in moderate to severe COPD patients. Expand
Is there any difference between effects of ipratropium bromide and formoterol on exercise capacity in moderate COPD patients?
TLDR
It is observed that ipratropium bromide and formoterol have similar improvement in Exercise capacity in COPD patients, and the improvement in exercise capacity also correlated with increase in FEV(1). Expand
Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD.
TLDR
Tiotropium in combination with PR improved endurance of a constant work rate treadmill task and produced clinically meaningful improvements in dyspnea and health status compared to PR alone. Expand
Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease.
TLDR
It is concluded that inhalation of furosemide alleviates the sensation of dyspnea induced by constant-load exercise testing in patients with COPD and that there is significant bronchodilation after inhalations of f Kurosemide compared with placebo in these patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 66 REFERENCES
Is an anticholinergic agent superior to a beta 2-agonist in improving dyspnea and exercise limitation in COPD?
TLDR
It is concluded that the effects of 1 week of albuterol or ipratropium have similar effects on exercise performance and subjective dyspnea in patients with stable COPD. Expand
Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease
TLDR
Although data based on short term effects cannot be directly applied to long term therapy, theophylline added to an inhaled anticholinergic agent may have beneficial effects on exercise capacity in patients with COPD. Expand
Effect of Terbutaline on Exercise Capacity and Pulmonary Function in Patients with Chronic Obstructive Pulmonary Disease
TLDR
It was concluded that despite significant improvements in resting lung function, inhalation of 2.5 mg of terbutaline did not increase exercise capacity, but it increased cumulative oxygen uptake and carbon dioxide elimination during exercise and recovery, presumably because of a thermogenic effect of ter butaline. Expand
Effect of theophylline on exercise performance in patients with severe chronic obstructive pulmonary disease.
TLDR
Theophylline improved cardiorespiratory performance in these patients with severe chronic obstructive pulmonary disease mainly by increasing the ventilatory capacity. Expand
Long-term effects of inhaled anticholinergic drug on lung function, dyspnea, and exercise capacity in patients with chronic obstructive pulmonary disease.
TLDR
The chronic use of an inhaled anticholinergic bronchodilator may provide beneficial improvements in expiratory flow rate, exercise performance, and dyspnea in mild to moderate COPD patients over one year. Expand
Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease.
TLDR
A dose of at least four times the standard dose of ipratropium bromide from an MDI with a spacer device was necessary to improve maximal cycle exercise capacity in patients with stable COPD. Expand
Effect of inhaled metaproterenol on exercise performance in patients with stable "fixed" airway obstruction.
TLDR
It is concluded that an objective improvement in physical performance after administration of a relatively high dose of inhaled metaproterenol can be seen in some patients with moderate to severe "fixed" airway obstruction, despite a lack of significant response as judged by conventional spirometry criteria. Expand
Oxitropium bromide improves exercise performance in patients with COPD.
TLDR
The inhalation of oxitropium bromide, 800 micrograms, can improve the exercise capacity of patients with stable COPD and it is suggested that the effect is due to the bronchodilation induced by this drug. Expand
Effect of increasing doses of beta agonists on spirometric parameters, exercise capacity, and quality of life in patients with chronic airflow limitation.
TLDR
Regular use of beta agonists in doses higher than two puffs four times a day is very unlikely to provide additional functional or symptomatic benefit to patients with chronic airflow limitation. Expand
Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease.
TLDR
Improvements in walking distances and symptoms were unrelated to changes in either FEV1 or FVC, indicating that routine reversibility testing is not a good predictor of symptomatic benefit in these patients. Expand
...
1
2
3
4
5
...